The Extracellular RNA (exRNA) Communication Consortium was launched by the National Institutes of Health to focus on the extent to which RNA might function in a non-cell-autonomous manner. With the availability of increasingly sensitive tools, small amounts of RNA can be detected in serum, plasma, and other bodily fluids. The exact mechanism(s) by which RNA can be secreted from cells and the mechanisms for the delivery and uptake by recipient cells remain to be determined. This review will summarize current knowledge about the biogenesis and delivery of exRNA and outline projects seeking to understand the functional impact of exRNA.
levels of RNAse in extracellular fluids and plasma that function to destroy foreign RNAs, most commonly viral RNA. However, new highly sensitive tools have enabled the discovery of extracellular host RNA in both the bloodstream and multiple body fluids (10) . How these RNAs are exported from donor cells, how they are taken up by and/or targeted to specific recipient cells, and how they are released to function inside recipient cells remain mostly unanswered questions. To address these questions, the National Institutes of Health Common Fund launched a new program, the Extracellular RNA (exRNA) Communication Consortium. This review will summarize the projects focusing on biogenesis and delivery mechanisms, and the function of exRNA.
RNA export
To avoid degradation, it is thought that most exRNAs are either encased within membranous vesicles or are tightly associated with proteins and/or lipids. Extracellular vesicles (EV) include exosomes ( Â40Á100 nm) and larger microvesicles but could conceivably also include apoptotic vesicles released upon cell death (11, 12) (Fig. 1) . Multiple studies have focused on exosomes as carriers of RNA, in part due to RNA sequencing/microarray studies performed from purified exosomes (13Á15), as well as localization of miRNA effector complexes associated with multivesicular bodies (MVBs) (16, 17) . Exosomes are endosomally derived vesicles that form by invagination into MVBs and contain proteins involved in endosomal transport and fusion (18) . Normally, MVBs are targeted to lysosomes for degradation, but they can also fuse with the plasma membrane, thereby releasing exosomes into the extracellular space. Deposition of some, but not all, RNAs into exosomes might be explained by import into MVBs during the intraluminal vesiculation process. This explains the presence of miRNAs in exosomes since the RISC machinery that processes miRNAs has been localized to the surface of MVBs (16, 17) . Exosomes that originate from MVBs and contain miRNAs may not necessarily require ESCRTS for assembly (19, 20) . Inhibition of ceramide synthesis by blocking neutral sphingomyelinases can cause a decrease in exosome release and secreted miRNAs, although this may be cell specific (21Á24). How longer RNAs, particularly mRNAs or long non-coding RNAs are targeted for export into exosomes or microvesicles is not clear (15, 25, 26) . From microarrays and RNA sequencing experiments, numerous sequences are detected from multiple classes of RNA, including rRNAs and mRNAs, but the abundance and activity of full-length mRNA remain uncertain (13, 15, 27, 28) . Similarly, it is not known if there is a size threshold for long non-coding RNAs. For these reasons, most work has focused on miRNA deposition into exosomes.
miRNAs can also be found in extracellular fluids in complex with either Argonaute proteins (29) or as part of lipoprotein particles, mostly HDL (30) . Quantitative analysis of miRNA content in exosomes has suggested that individual exosomes contain vanishingly small numbers of miRNA molecules, far lower than would be expected if exported miRNAs function stoichiometrically in recipient cells (31) . While somewhat controversial, one explanation to account for these results is that different subclasses of exosomes exist, only some of which contain miRNAs or other RNAs. A second possibility is that functional miRNA is transported via Ago2 complexes or as part of HDL particles (Fig. 1) . Stoichiometric concerns Biogenesis and uptake of exRNA. Endocytosis is commonly mediated via clathrin-coated pits (1) after which endocytic vesicles progress from early (2) to late endosomes, also referred to as multivesicular bodies (MVBs). MVBs often fuse with lysosomes for degradation (4) but can also fuse with the plasma membrane (5) thereby releasing exosomes (40Á100 nm) to the extracellular space. Microvesicles are larger fragments of plasma membrane that are shed from almost all cells (6 
Delivery of exRNA
After export from donor cells, proposed mechanisms for how RNAs are delivered to recipient cells depend on whether they are part of exosomes (or other vesicles), HDL, or Ago2 complexes (Fig. 1) . Receptor-mediated uptake would be expected for HDL-associated miRNAs (scavenger receptor class B type 1) (30) and exosomes by a variety of membrane receptors matched to exosomal ligands (23,27,36Á38). It is not clear how recipient cells would take up Ago2-miRNA complexes. Receptors exist to transfer double-stranded RNA in Caenorhabditis elegans, mammals (39), flies (40) , and plants (41) . It will be interesting to determine what role such receptors/ pathways play in mediating the uptake of exRNA.
Functional transfer of exRNA
The greatest short-term impact of the discovery of exRNA might be the identification of biomarkers of disease because it does not involve functional transfer of RNA to recipient cells (42) . However, if RNAs are specifically targeted for export and cells use receptor-mediated mechanisms to uptake specific particles or complexes, a logical extension is that gene expression patterns in recipient cells should be altered. Exosomes can mediate functional effects in recipient cells, but whether RNA is essential and the extent to which gene expression can be altered remain to be precisely determined. In models of colorectal cancer, exosomes released from KRAS mutant cell lines can increase the invasiveness of recipient cells, but this could be due to transfer of mutant KRAS via EGFR ligand signalling or other protein-mediated mechanisms (37, 43) . Among other examples, exosomal transfer from stromal to breast cancer cells can alter radiation sensitivity (44) , exosomes released from cardiosphere-derived cells can promote proliferation of cardiomyocytes (45) , glioblastoma microvesicle transfer can promote tumour growth (15) , EVs can transfer between endothelial cells and smooth muscle cells for atheroprotective communication (46) , exosomal transfer of miR-146a from endothelial cells to cardiomyocytes can alter metabolism (47) , and exosomal transfer of miRNAs and miRNA processing machinery can occur between tumorigenic and non-tumorigenic cells (48) . In all these cases, exRNA transfer may play a significant role, but the exact extent to which the effects are RNA mediated remains to be determined. For RNA transfer, exosomes can indeed transfer miRNAs but the experiments to demonstrate such transfer often involve culturing recipient cells with largely non-physiological concentrations of exosomes (15, 27, 36, 49, 50) . To attempt to recapitulate more physiological conditions, co-culture experiments, Transwell experiments, systemic injection of exosomes, implantation of Matrigel plugs containing exosomes, and xenograft experiments have all shown that exosomal contents can be transferred to some extent to recipient cells (23,44,45,49Á51) .
While many of the above experiments show that exRNA can be delivered, it remains unclear how these RNAs are released for functional activity upon entry into recipient cells. As discussed above, miRNA function is particularly challenging since stoichiometric delivery would seem to be required to effect significant changes in gene expression (31) . One possibility is that delivery of exRNAs might induce changes reminiscent of immune activation. miRNAs are ligands of Toll-like receptors and as such could conceivably mediate their effects by activating downstream signalling cascades (52, 53) . Antiviral immunity is often conferred by recognition of RNAs bearing 5? disphosphates by Rig-1 (54) . Interestingly, transfer of RNA from stromal to breast cancer cells within exosomes stimulates RIG-1 to activate STAT1 signalling (44) .
In summary, with the availability of increasingly sensitive tools, there is little doubt that exRNAs exist. However, mechanistic understanding of how RNAs are released from cells and how or whether they can be specifically targeted to recipient cells to alter gene expression patterns remains mostly unknown. To tackle these questions, 5 groups within the exRNA Communication Consortium are studying the biogenesis of exRNA.
exRNA released by glioblastoma alters brain microenvironment (Dr. Xandra Breakefield, Principal Investigator, Harvard Medical School, Massachusetts General Hospital) The unifying theme of the Breakefield group focuses on biogenesis and release of exRNA by glioblastoma (GBM) and modes of uptake and functional consequences in normal cells in the brain microenvironment. Our overriding hypothesis is that GBM release exRNAs that are taken up by normal cells in their environs and change their gene expression, which, in turn, determines the malignant potential of the tumour and host response. GBMs represent one of the most common and aggressive brain tumours in humans, with time from diagnosis to death a. Development of a highly robust ''pOSI-sensor'' technology to report on exRNA uptake and activity in cells. In contrast to negative sensors, such sensors allow for the detection of exRNA transport in single cells. This feature is important as it is expected that within tissues, exRNA mode of action will be tightly regulated, notably by cell differentiation, external stimuli, and/or by the expression of specific licensing factors. By combining the use of miRNA pOSI sensors with corresponding miRNA knockout mice, these experiments will be able to exclude the contribution of endogenous miRNA in recipient cells. b. Detect local or systemic functional exRNA transfer events in diverse normal or pathological situations such as those occurring in tumourÁhost communication, secreting epithelia and muscle development, and digestion of breast milk or dietary plant-derived RNAs. c. Systematically investigate cell-to-cell miRNA transfer in a wide array of tissues using a mouse chimera approach. d. Determine the role of mammalian homologs of C.
elegans sid-1 RNA transporter (SidT1 and SidT2).
RNA transport defects in SidT1/2 mice will be used to identify exRNAs that require these proteins for their accumulation (or depletion) in cell culture medium and body fluids, and will notably adapt RNA-tagging and pOSI-sensor strategies to efficiently detect their functional transfer. e. Investigate the mechanisms of Argonaute release in the extracellular space. Association of Argonaute proteins with the endomembrane system is clearly important for the activity and recycling of small RNAs in cells but its impact on the extracellular release of Argonaute remains unclear. We have developed a unique cellular system allowing us to manipulate the association of Argonautes to a diverse array of endomembranes, which will allow us to identify key cellular compartments supporting extracellular Argonaute accumulation and also identification of cellular co-factors involved in this process. Lastly, we are investigating the behaviour and possible uptake of extracellular Argonautes in vivo using a combination of transgenic and knockout animals. 
